Trump Imposes 200 Percent Tariff on Generic Drugs, Threatening $9.7 Billion Indian Export Market

Trump announces a two‑stage tariff on imported generic medicines, starting at zero percent and climbing to 200 percent after a two‑year period, targeting the United States’ reliance on foreign drug supplies and aiming to protect domestic manufacturers.

Indian pharmaceutical exporters face potential loss of roughly $9.7 billion in annual sales, as the United States accounts for a large share of their generic drug market, prompting concerns over trade balance.

CEO of a leading Indian pharma firm warns that the tariff could push U.S. generic drug prices higher, reduce patient access, and force Indian companies to seek alternative markets or absorb cost cuts.

Trade analysts note the move reflects broader U.S. onshoring strategy, may strain India‑U.S. trade relations, and could trigger retaliatory measures, while highlighting the geopolitical importance of India’s pharma sector.